miR‑383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24‑mediated NF‑κB signaling pathway

He,Bo; Wu,Chao; Sun,Weichao; Qiu,Yang; Li,Jingyao; Liu,Zhihui; Jing,Tao; Wang,Haidong; Liao,Yi

doi:10.3892/ijo.2021.5267

miR‑383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24‑mediated NF‑κB signaling pathway

Authors:
- Bo He
- Chao Wu
- Weichao Sun
- Yang Qiu
- Jingyao Li
- Zhihui Liu
- Tao Jing
- Haidong Wang
- Yi Liao
View Affiliations

Affiliations: Department of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, P.R. China, The Central Laboratory, Shenzhen Second People's Hospital, Shenzhen University First Affiliated Hospital, Shenzhen, Guangdong 518035, P.R. China, Department of Cardiology, Southwest Hospital, Army Medical University, Chongqing 400038, P.R. China
Published online on: September 22, 2021 https://doi.org/10.3892/ijo.2021.5267
Article Number: 87
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of microRNA‑383 (miR‑383) is downregulated in a variety of tumor tissues, and it exhibits antiproliferative activity in non‑small cell lung cancer cells. In the present study, an association between the downregulation of miR‑383 expression and the deletion of chr8p22 in patients with lung adenocarcinoma was identified. The promoting effect of miR‑383 on cisplatin sensitivity was verified both in vivo and in vitro. Additionally, it was revealed that the expression of RNA binding motif protein 24 (RBM24) protein was regulated by and negatively correlated with miR‑383 expression. Ectopic expression of RBM24 or inhibition of miR‑383 decreased the chemosensitivity of parental A549 cells, whereas knockdown of RBM24 in cisplatin‑resistant A549 cells increased chemosensitivity. Mechanistically, miR‑383 interfered with the activation of nuclear factor κB (NF‑κB) signaling through repression of RBM24‑mediated phosphorylation of Rel‑like domain‑containing protein A and inhibitor α of NF‑κB. Taken together, the downregulation of miR‑383 induced RBM24 expression, which was mediated through the activation of NF‑κB signaling, to contribute to chemotherapy resistance in lung adenocarcinoma cells. The results of the present study highlight potential therapeutic targets for the clinical reversal of the chemotherapy resistance in lung adenocarcinoma.

View Figures

View References

1	Schwartz AG and Cote ML: Epidemiology of lung cancer. Adv Exp Med Biol. 893:21–41. 2016. View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar
3	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar
4	Xiong Y, Huang BY and Yin JY: Pharmacogenomics of platinum- based chemotherapy in non- small cell lung cancer: Focusing on DNA repair systems. Med Oncol. 34:482017. View Article : Google Scholar
5	Denisenko TV, Budkevich IN and Zhivotovsky B: Cell death- based treatment of lung adenocarcinoma. Cell Death Dis. 9:1172018. View Article : Google Scholar
6	Zhao J, Xu T, Wang F, Cai W and Chen L: miR- 493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73. Biomed Pharmacother. 90:744–751. 2017. View Article : Google Scholar
7	Yu X and Li Z: MicroRNA expression and its implications for diagnosis and therapy of tongue squamous cell carcinoma. J Cell Mol Med. 20:10–16. 2016. View Article : Google Scholar
8	Gao Y, Luo LH, Li S and Yang C: miR- 17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun. 444:230–234. 2014. View Article : Google Scholar
9	Yue LU, Xiang JY, Sun P, Yao YS, Sun ZN, Liu XP, Wang HB, Shen Z and Yao RY: Relationship between HSP70 and ERBB2 expression in breast cancer cell lines regarding drug resistance. Anticancer Res. 36:1243–1249. 2016.
10	Yu X, Li Z, Chan MT and Wu WK: microRNA deregulation in keloids: An opportunity for clinical intervention? Cell Prolif. 48:626–630. 2015. View Article : Google Scholar
11	Pan JY, Zhang F, Sun CC, Li SJ, Li G, Gong FY, Bo T, He J, Hua RX, Hu WD, et al: miR- 134: A human cancer suppressor? Mol Ther Nucleic Acids. 6:140–149. 2017. View Article : Google Scholar
12	Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W and Wang L: MicroRNA- 381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017. View Article : Google Scholar
13	Yu X, Li Z, Yu J, Chan MTV and Wu WKK: MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. 48:503–510. 2015. View Article : Google Scholar
14	Pei K, Zhu JJ, Wang CE, Xie QL and Guo JY: MicroRNA- 185-5p modulates chemosensitivity of human non- small cell lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol Sci. 20:4697–4704. 2016.
15	Yu S, Qin X, Chen T, Zhou L, Xu X and Feng J: MicroRNA- 106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease- 2 in non- small- cell lung cancer. Anticancer Drugs. 28:852–860. 2017. View Article : Google Scholar
16	Gang H, Pan J, Ye Z, Fang B and Wei C: Overexpression of miR- 216b sensitizes NSCLC cells to cisplatin- induced apoptosis by targeting c- Jun. Oncotarget. 8:104206–104215. 2017. View Article : Google Scholar
17	Azarbarzin S, Feizi MAH, Safaralizadeh R, Kazemzadeh M and Fateh A: The value of miR- 383, an intronic miRNA, as a diagnostic and prognostic biomarker in intestinal- type gastric cancer. Biochem Genet. 55:244–252. 2017. View Article : Google Scholar
18	Bucay N, Sekhon K, Yang T, Majid S, Shahryari V, Hsieh C, Mitsui Y, Deng G, Tabatabai ZL, Yamamura S, et al: MicroRNA- 383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. Oncogene. 36:2667–2679. 2017. View Article : Google Scholar
19	Shang Y, Zang A, Li J, Jia Y, Li X, Zhang L, Huo R, Yang J, Feng J, Ge K, et al: MicroRNA- 383 is a tumor suppressor and potential prognostic biomarker in human non- small cell lung caner. Biomed Pharmacother. 83:1175–1181. 2016. View Article : Google Scholar
20	Ma H, Liu B, Wang S and Liu J: MicroRNA- 383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain- containing protein 1. Cell Biochem Funct. 34:613–619. 2016. View Article : Google Scholar
21	Tan W, Liao Y, Qiu Y, Liu H, Tan D, Wu T, Tang M, Zhang S and Wang H: miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP). Cancer Lett. 428:55–68. 2018. View Article : Google Scholar
22	Wagenaar SS: New WHO- classification of lung and pleural tumors. Ned Tijdschr Geneeskd. 143:984–990. 1999.In Dutch.
23	Tsim S, O'Dowd CA, Milroy R and Davidson S: Staging of non- small cell lung cancer (NSCLC): A review. Respir Med. 104:1767–1774. 2010. View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real- time quantitative PCR and the 2(- Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Lee S, Kopp F, Chang TC, Sataluri A, Chen B, Sivakumar S, Yu H, Xie Y and Mendell JT: Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. 164:69–80. 2016. View Article : Google Scholar
26	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press; Washington DC: 2011
27	Shanker M, Willcutts D, Roth JA and Ramesh R: Drug resistance in lung cancer. Lung Cancer (Auckl). 1:23–36. 2010.
28	Panwar B, Omenn GS and Guan Y: miRmine: A database of human miRNA expression profiles. Bioinformatics. 33:1554–1560. 2017.
29	Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E and Keller A: Distribution of miRNA expression across human tissues. Nucleic Acids Res. 44:3865–3877. 2016. View Article : Google Scholar
30	Wan P, Chi X, Du Q, Luo J, Cui X, Dong K, Bing Y, Heres C and Geller DA: miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. J Cell Biochem. 119:9720–9729. 2018. View Article : Google Scholar
31	Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H and Sakuragi N: Correction: Control of PD- L1 expression by miR- 140/142/340/383 and oncogenic activation of the OCT4- miR- 18a pathway in cervical cancer. Oncogene. 38:39722019. View Article : Google Scholar
32	Zhao S, Gao X, Zang S, Li Y, Feng X and Yuan X: MicroRNA- 383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A. Oncol Lett. 14:3573–3579. 2017. View Article : Google Scholar
33	Mu X, Wu H, Liu J, Hu X, Wu H, Chen L, Liu W, Luo S and Zhao Y: Long noncoding RNA TMPO- AS1 promotes lung adenocarcinoma progression and is negatively regulated by miR- 383-5p. Biomed Pharmacother. 125:1099892020. View Article : Google Scholar
34	Piovani G, Savio G, Traversa M, Pilotta A, De Petro G, Barlati S and Magri C: De novo 1Mb interstitial deletion of 8p22 in a patient with slight mental retardation and speech delay. Mol Cytogenet. 7:252014. View Article : Google Scholar
35	Chi C, Murphy LC and Hu P: Recurrent copy number alterations in young women with breast cancer. Oncotarget. 9:11541–11558. 2018. View Article : Google Scholar
36	Tsubaki M, Ogawa N, Takeda T, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Satou T and Nishida S: Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down- regulation of Bcl- xL and XIAP. Biomed Pharmacother. 68:999–1005. 2014. View Article : Google Scholar
37	Viatour P, Merville MP, Bours V and Chariot A: Phosphorylation of NF- kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci. 30:43–52. 2005. View Article : Google Scholar
38	Chen Y, Wang D, Peng H, Chen X, Han X, Yu J, Wang W, Liang L, Liu Z, Zheng Y, et al: Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI- PLCε- NF-κB signaling pathway and VEGF- C/Bcl- 2 expression. Mol Cancer. 18:12019. View Article : Google Scholar
39	Bravo-Cuellar A, Hernández- Flores G, Lerma- Díaz JM, Domínguez- Rodríguez JR, Jave-Suárez LF, De Célis- Carrillo R, Aguilar- Lemarroy A, Gómez-Lomeli P and Ortiz-Lazareno PC: Pentoxifylline and the proteasome inhibitor MG132 induce apoptosis in human leukemia U937 cells through a decrease in the expression of Bcl- 2 and Bcl- XL and phosphorylation of p65. J Biomed Sci. 20:132013. View Article : Google Scholar
40	Yao Y, Yang B, Cao H, Zhao K and Chen X: RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence. Emerg Microbes Infect. 7:862018. View Article : Google Scholar
41	Hua WF, Zhong Q, Xia TL, Chen Q, Zhang MY, Zhou AJ, Tu ZW, Qu C, Li MZ, Xia YF, et al: RBM24 suppresses cancer progression by upregulating miR- 25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death Dis. 7:e23522016. View Article : Google Scholar
42	Xu E, Zhang J, Zhang M, Jiang Y, Cho SJ and Chen X: RNA- binding protein RBM24 regulates p63 expression via mRNA stability. Mol Cancer Res. 12:359–369. 2014. View Article : Google Scholar
43	Zhang Q, Wang YZ, Zhang W, Chen X, Wang J, Chen J and Luo W: Involvement of cold inducible RNA- binding protein in severe hypoxia- induced growth arrest of neural stem cells in vitro. Mol Neurobiol. 54:2143–2153. 2016. View Article : Google Scholar